AFFILIATIONS
1 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
2 Fred Hutch Cancer Center, Seattle, Washington, United States
3 Fred Hutch Cancer Center, Seattle, Washington, United States, Seattle Children's Research Institute, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
4 Fred Hutch Cancer Center, Seattle, Washington, United States
5 Fred Hutch Cancer Center, Seattle, Washington, United States
6 Fred Hutch Cancer Center, Seattle, Washington, United States
7 Seattle Children's Research Institute, Seattle, Washington, United States
8 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
9 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
10 Fred Hutch Cancer Center, Seattle, Washington, United States
11 Fred Hutch Cancer Center, Seattle, Washington, United States
12 Fred Hutch Cancer Center, Seattle, Washington, United States
13 Fred Hutch Cancer Center, Seattle, Washington, United States
14 Fred Hutch Cancer Center, Seattle, Washington, United States
15 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
16 Fred Hutch Cancer Center, Seattle, Washington, United States
17 Fred Hutch Cancer Center, Seattle, Washington, United States
18 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
19 Fred Hutch Cancer Center, Seattle, Washington, United States
20 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
21 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
22 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
23 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
24 Fred Hutch Cancer Center, Seattle, Washington, United States, Royal North Shore Hospital, St. Leonards, Australia, University of Sydney, Sydney, Australia
25 Fred Hutch Cancer Center, Seattle, Washington, United States
26 Seattle Children's Research Institute, Seattle, Washington, United States
27 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
28 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
29 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
ABSTRACT
Background
We previously reported outcomes from a phase 2 investigator-initiated clinical trial of prophylaxis with the recombinant IL-1 receptor antagonist anakinra (anakinra ppx; given days 0-13) to prevent CRS and ICANS in patients with large B-cell lymphoma (LBCL) receiving CD19 CAR T-cell therapy with lisocabtagene maraleucel (liso-cel; NCT04359784; Liang et al., Tandem Meetings 2026). Our study did not meet its primary endpoint of any-grade CRS reduction, though patients who received anakinra ppx had lower ICANS severity and shorter ICANS duration. We performed multiomic single-cell analyses on longitudinal patient samples to examine the cellular and molecular drivers of CRS and ICANS as well as potential mechanisms of resistance to anakinra ppx.
Methods
Blood samples were obtained at pre-lymphodepletion, day 0 pre-infusion, and days 1, 3, 7, 10, 14, and 28. Peripheral blood mononuclear cell samples were profiled using single-cell RNA sequencing (scRNA-seq; 10X Genomics 5’ GEMX) and spectral flow cytometry. Whole blood samples were analyzed using mass cytometry (CyTOF). Statistical significance was defined as a false discovery rate < 0.2.
Results
Ten patients who received liso-cel alone and 10 who received liso-cel + IV anakinra ppx were included. First, we evaluated CAR T- and endogenous T-cell populations stratified by toxicity and receipt of anakinra ppx. A total of 269,535 T cells, including 13,345 CAR T cells, were annotated by scRNA-seq. Uniform Manifold Approximation and Projection with Leiden clustering separated 15 distinct T-cell subsets that were mapped to canonical functional states. We did not observe differences in T-cell or CAR T-cell cluster abundances by receipt of anakinra ppx. However, CRS was associated with a significantly lower frequency of CD4-expressing CAR T cells harboring a regulatory T-cell-like (CAR Treg) transcriptional profile at day 3. Spectral flow cytometry confirmed a significantly lower frequency of CD4+ CAR Treg cells at day 10 in patients with CRS and ICANS. CRS and ICANS were also associated with a significantly higher frequency of CD8-expressing CAR T cells with increased expression of genes associated with T-cell activation (CD69, ICOS) and NF-κB signaling (NFKB1, NFKBIA) at day 10. In contrast, ICANS was associated with a significantly lower frequency of a CD8-expressing CAR T-cell subset with increased expression of genes associated with a memory/stem-like state (TCF7, CCR7, SELL, LEF1) at day 10.
Next, we sought to identify myeloid programs associated with breakthrough toxicities despite IL-1 blockade. In scRNA-seq analysis of 207,589 myeloid cells, we identified two CD163-expressing classical monocyte populations (cMono1 and cMono2) that were associated with CRS and ICANS rather than CRS alone. In patients with CRS and ICANS, the frequency of cMono1 was significantly higher at day 3, and this population was significantly enriched for expression of IL10, JAK/STAT3 signaling-related genes (EBI3, IL1R2, IL2RA), and interferon-related genes (IFIT1, CXCL10, ISG15). The frequency of cMono1 was similar in patients who received anakinra ppx vs. liso-cel alone. CyTOF confirmed an analogous CD163+ classical monocyte population significantly associated with ICANS; within this population, we observed higher expression of phosphorylated (p)STAT3 at day 7 in patients with ICANS. This CD163+ classical monocyte population was also enriched in patients who received anakinra ppx and developed breakthrough toxicities. In contrast, the frequency of cMono2 was significantly higher at day 10 in patients with CRS and ICANS, but lower in patients who received anakinra ppx. cMono2 was significantly enriched for expression of IL1R1, IL1R2, and IL1RAP.
Conclusion
We identified CAR T-cell and monocyte populations associated with CRS and ICANS in patients with LBCL treated with liso-cel. A lower frequency of CD4+ CAR Treg cells was associated with CRS, and a higher frequency of CD163+ classical monocytes was associated with ICANS. While anakinra ppx suppressed an IL1-responsive cMono2 population, we observed the early expansion of an IL-1 blockade-resistant cMono1 population that was strongly correlated with CRS and ICANS and characterized by a JAK/STAT3 gene signature and increased intracellular pSTAT3. Our findings suggest that CRS and ICANS following CD19 CAR T-cell therapy are associated with JAK/STAT3-driven monocytes, supporting evaluation of targeted approaches against this pathway.